Helping families take charge of adenosine deaminase (ADA)-severe combined immunodeficiency (SCID)

Although rare, adenosine deaminase (ADA)-severe combined immunodeficiency (SCID) is one of the most serious primary immunodeficiencies (PI). Children with ADA-SCID lack immune protection against bacteria, viruses, and fungi and are prone to repeated and persistent infections. Fortunately, effective treatments exist that can treat the disorder.

Join the Immune Deficiency Foundation (IDF) as we speak with Dr. Donald Kohn, Professor of Microbiology, Immunology & Molecular Genetics and Pediatrics at UCLA to answer your questions about this rare diagnosis and to explore the treatment options in our latest webinar.

We appreciate Dr. Kohn helping us better understand ADA-SCID. Do you have a topic that you would like IDF to feature in a webinar? Let us know. Click here to e-mail us with your suggestion.

This webinar was supported by Leadiant Biosciences.

This content should not be used as a substitute for professional medical advice. In all cases, patients and caregivers should consult their healthcare providers. Each patient’s condition and treatment is unique. The benefits and risks of any treatment should be discussed with the patient’s provider.